Supply issues weigh on Novo Nordisk as drugmaker stumbles with quarterly report

Taking stock of the drug industry, from the lab to the medicine chest

August 7, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

LISELOTTE SABROE/Scanpix/AFP via Getty Images STAT+ | Supply issues weigh on Novo Nordisk as drugmaker stumbles with quarterly report Novo executives said they are improving the supply of its blockbuster obesity and diabetes medications, which should increase sales. By Andrew Joseph STAT+ | FDA scolds Bristol Myers over a misleading website for a cancer treatment "The calculations … are not supported by the data cited" in the study touted on the website, the FDA warned Bristol Myers. By Ed Silverman Opinion: Give pharmaceutical execs the benefit of doubt — but they need to work for it Pharmaceutical leaders have been portrayed as rapacious execs who gouge patients to gratify shareholders. They face competing pressures. By Fred D. Ledley Bloomberg STAT+ | Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data The company plans to reapply next year when it has more data on complications such as hospitalizations and cardiovascular-related deaths. By Elaine Chen and Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser